Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Growth differentiation factor 15 is decreased by kidney transplantation.

Connelly PW, Yan AT, Nash MM, Lok CE, Gunaratnam L, Prasad GVR.

Clin Biochem. 2019 Nov;73:57-61. doi: 10.1016/j.clinbiochem.2019.07.013. Epub 2019 Jul 27.

PMID:
31361994
2.

Serum Apolipoprotein B and A1 Concentrations Predict Late-Onset Posttransplant Diabetes Mellitus in Prevalent Adult Kidney Transplant Recipients.

Malyala R, Rapi L, Nash MM, Prasad GVR.

Can J Kidney Health Dis. 2019 May 25;6:2054358119850536. doi: 10.1177/2054358119850536. eCollection 2019.

3.

Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.

Prasad GVR, Beckley J, Mathur M, Gunasekaran M, Nash MM, Rapi L, Huang M, Zaltzman JS.

BMC Infect Dis. 2019 Apr 5;19(1):311. doi: 10.1186/s12879-019-3944-0.

4.

Monitoring Kidney Dysfunction in Kugelberg-Welander Syndrome.

West M, Nash MM, Rapi L, Krizova A, Prasad GVR.

Am J Case Rep. 2019 Apr 3;20:441-446. doi: 10.12659/AJCR.914458.

5.

Pre-Transplant Left Ventricular Geometry and Major Adverse Cardiovascular Events After Kidney Transplantation.

Malyala R, Rapi L, Nash MM, Prasad GVR.

Ann Transplant. 2019 Feb 21;24:100-107. doi: 10.12659/AOT.913649.

6.

Cardiovascular magnetic resonance left ventricular strain in end-stage renal disease patients after kidney transplantation.

Gong IY, Al-Amro B, Prasad GVR, Connelly PW, Wald RM, Wald R, Deva DP, Leong-Poi H, Nash MM, Yuan W, Gunaratnam L, Kim SJ, Lok CE, Connelly KA, Yan AT.

J Cardiovasc Magn Reson. 2018 Dec 17;20(1):83. doi: 10.1186/s12968-018-0504-5.

7.

Determinants of Left Ventricular Characteristics Assessed by Cardiac Magnetic Resonance Imaging and Cardiovascular Biomarkers Related to Kidney Transplantation.

Prasad GVR, Yan AT, Nash MM, Kim SJ, Wald R, Wald R, Lok C, Gunaratnam L, Karur GR, Kirpalani A, Connelly PW.

Can J Kidney Health Dis. 2018 Nov 9;5:2054358118809974. doi: 10.1177/2054358118809974. eCollection 2018.

8.

The Impact of Total Gastrectomy on Pharmacokinetics in Kidney Transplant Immunosuppressive Drug Regimes: A Case Study.

Chen L, Liberatore L, Chin T, Walker S, Fanous H, Nash MM, Rapi L, Huckle J, Zaltzman JS, Prasad GVR.

Transplantation. 2017 Sep;101(9):2213-2217. doi: 10.1097/TP.0000000000001507.

PMID:
27748705
9.

Commercial kidney transplantation is an important risk factor in long-term kidney allograft survival.

Prasad GVR, Ananth S, Palepu S, Huang M, Nash MM, Zaltzman JS.

Kidney Int. 2016 May;89(5):1119-1124. doi: 10.1016/j.kint.2015.12.047. Epub 2016 Mar 9.

PMID:
27083285
10.

Metabolic syndrome definitions and components in predicting major adverse cardiovascular events after kidney transplantation.

Prasad GV, Huang M, Silver SA, Al-Lawati AI, Rapi L, Nash MM, Zaltzman JS.

Transpl Int. 2015 Jan;28(1):79-88. doi: 10.1111/tri.12450. Epub 2014 Oct 7.

11.

A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study.

Fanous H, Zheng R, Campbell C, Huang M, Nash MM, Rapi L, Zaltzman JS, Prasad GV.

Clin Kidney J. 2013 Feb;6(1):45-49. Epub 2012 Jan 1.

12.

Room temperature self-assembly of mixed nanoparticles into photonic structures.

Naqshbandi M, Canning J, Gibson BC, Nash MM, Crossley MJ.

Nat Commun. 2012;3:1188. doi: 10.1038/ncomms2182.

PMID:
23149733
13.

Paraoxonase 1 Phenotype and Mass in South Asian versus Caucasian Renal Transplant Recipients.

Connelly PW, Maguire GF, Nash MM, Rapi L, Yan AT, Prasad GV.

J Lipids. 2012;2012:608580. doi: 10.1155/2012/608580. Epub 2012 Jun 3.

14.

Lower total and percent of high-molecular-weight adiponectin concentration in South Asian kidney transplant recipients.

Prasad GV, Vorobeichik L, Nash MM, Huang M, Rapi L, Maguire G, Mamdani M, Yan AT, Connelly PW.

Clin Kidney J. 2012 Apr;5(2):124-129.

15.

Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients.

Silver SA, Huang M, Nash MM, Prasad GV.

Transplantation. 2011 Jul 27;92(2):183-9. doi: 10.1097/TP.0b013e31821f303f.

PMID:
21558986
16.

South Asian ethnicity as a risk factor for major adverse cardiovascular events after renal transplantation.

Prasad GV, Vangala SK, Silver SA, Wong SC, Huang M, Rapi L, Nash MM, Zaltzman JS.

Clin J Am Soc Nephrol. 2011 Jan;6(1):204-11. doi: 10.2215/CJN.03100410. Epub 2010 Sep 30.

17.

A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada.

Prasad GV, Nash MM, Keough-Ryan T, Shapiro RJ.

J Nephrol. 2010 May-Jun;23(3):274-81.

PMID:
20383867
18.

Twenty four-hour ambulatory blood pressure profiles 12 months post living kidney donation.

Ramesh Prasad GV, Lipszyc D, Sarker S, Huang M, Nash MM, Rapi L.

Transpl Int. 2010 Aug;23(8):771-6. doi: 10.1111/j.1432-2277.2009.01040.x. Epub 2010 Jan 6.

19.

Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk.

Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV.

Am J Cardiol. 2009 Mar 15;103(6):867-71. doi: 10.1016/j.amjcard.2008.11.042. Epub 2009 Jan 24.

PMID:
19268747
20.

Pre-transplantation glucose testing for predicting new-onset diabetes mellitus after renal transplantation.

Ramesh Prasad GV, Huang M, Bandukwala F, Nash MM, Rapi L, Montada-Atin T, Meliton G, Zaltzman JS.

Clin Nephrol. 2009 Feb;71(2):140-6.

PMID:
19203506
21.

A prospective observational study of changes in renal function and cardiovascular risk following living kidney donation.

Prasad GV, Lipszyc D, Huang M, Nash MM, Rapi L.

Transplantation. 2008 Nov 15;86(9):1315-8. doi: 10.1097/TP.0b013e318188425b.

PMID:
19005415
22.

A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients.

Kim SJ, Prasad GV, Huang M, Nash MM, Famure O, Park J, Thenganatt MA, Chowdhury N, Cole EH, Fenton SS, Cattran DC, Zaltzman JS, Cardella CJ.

Transplantation. 2006 Oct 15;82(7):924-30.

PMID:
17038908
23.

The role of dietary cations in the blood pressure of renal transplant recipients.

Ramesh Prasad GV, Huang M, Nash MM, Zaltzman JS.

Clin Transplant. 2006 Jan-Feb;20(1):37-42.

PMID:
16556151
24.

Role of dietary salt intake in posttransplant hypertension with tacrolimus-based immunosuppression.

Prasad GV, Huang M, Nash MM, Zaltzman JS.

Transplant Proc. 2005 May;37(4):1896-7.

PMID:
15919496
25.

Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins).

Prasad GV, Kim SJ, Huang M, Nash MM, Zaltzman JS, Fenton SS, Cattran DC, Cole EH, Cardella CJ.

Am J Transplant. 2004 Nov;4(11):1897-903.

26.

Handwashing precautions taken by renal transplant recipients for severe acute respiratory syndrome.

Prasad GV, Nash MM, Zaltzman JS.

Transplantation. 2004 Jun 27;77(12):1917. No abstract available.

PMID:
15223923
27.

A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.

Prasad GV, Nash MM, McFarlane PA, Zaltzman JS.

Nephron Clin Pract. 2004;97(2):c35-40.

PMID:
15218328
28.

Statin use and bone mineral density in renal transplant recipients.

Prasad GV, Chiu R, Nash MM, Zaltzman JS.

Am J Transplant. 2003 Oct;3(10):1320-1. No abstract available.

29.

Renal transplant recipient attitudes toward steroid use and steroid withdrawal.

Prasad GV, Nash MM, McFarlane PA, Zaltzman JS.

Clin Transplant. 2003 Apr;17(2):135-9.

PMID:
12709080
30.

A prospective study of the physician effect on blood pressure in renal-transplant recipients.

Prasad GV, Nash MM, Zaltzman JS.

Nephrol Dial Transplant. 2003 May;18(5):996-1000.

PMID:
12686677
31.

Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients.

Prasad GV, Ahmed A, Nash MM, Zaltzman JS.

Kidney Int. 2003 Jan;63(1):360-4.

32.

Seasonal variation in outpatient blood pressure in stable renal transplant recipients.

Prasad GV, Nash MM, Zaltzman JS.

Transplantation. 2001 Dec 15;72(11):1792-4.

PMID:
11740390
33.
34.

Corneal Langerhans cell dynamics after herpes simplex virus reactivation.

Miller JK, Laycock KA, Nash MM, Pepose JS.

Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2282-90.

PMID:
8389344
35.

Personality characteristics of volunteers for medical research.

Walsh JA, Nash MM.

Crim Justice Behav. 1978 Jun;5(2):99-116. No abstract available.

PMID:
11662773
36.

A Micro-Mult for screening psychiatric disturbance.

Nash MM.

Psychol Rep. 1978 Jun;42(3 PT 1):985-6. No abstract available.

PMID:
674525
37.

"Nonreactive methods and the law": additional comments on legal liability in behavior research.

Nash MM.

Am Psychol. 1975 Jul;30(7):777-80. No abstract available.

PMID:
11643291
38.

Auditory comprehension and age.

Nash MM, Wepman JM.

Gerontologist. 1973 Summer;13(2):243-7. No abstract available.

PMID:
4710915
39.

Prediction of reaction to placebo.

Nash MM, Zimring FM.

J Abnorm Psychol. 1969 Oct;74(5):568-73. No abstract available.

PMID:
5349398
40.

Judicial application of behavioral concepts.

Nash MM.

Psychol Rep. 1968 Aug;23(1):245-6. No abstract available.

PMID:
5685398

Supplemental Content

Support Center